{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:53:56Z","timestamp":1787032436935,"version":"build-2736575974"},"reference-count":196,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>The presence of monoclonal proteins is common, with a prevalence in the United States around 5% that increases with age. Although most patients are asymptomatic, most cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma. In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. This review summarizes the current diagnosis treatment guidelines for MGUS and SMM and highlights recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7660","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T15:47:14Z","timestamp":1607356034000},"page":"1720-1729","source":"Crossref","is-referenced-by-count":11,"title":["Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma"],"prefix":"10.6004","volume":"18","author":[{"given":"Timothy M.","family":"Schmidt","sequence":"first","affiliation":[{"name":"1Winship Cancer Institute, Emory University, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"2University of Wisconsin Carbone Cancer Center, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.70.4.399","article-title":"Electrophoretic patterns of normal and pathological human blood serum and plasma","volume":"70","author":"Longsworth","year":"1939","journal-title":"J Exp Med"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"ref1991","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"key":"ref981","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128519","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"134","author":"Bustoros","year":"2019","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat Genet"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ejrad.2013.08.036","article-title":"Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM)","volume":"82","author":"Ippolito","year":"2013","journal-title":"Eur J Radiol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref1291","first-page":"243","article-title":"Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","article-title":"Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)","volume":"38","author":"Gleeson","year":"2009","journal-title":"Skeletal Radiol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(09)70234-7","article-title":"Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study","volume":"10","author":"Grass","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref951","article-title":"Guidelines in Multiple Version Accessed To view the most recent version visitNCCN org","volume":"20","author":"KumarSK","year":"2021","journal-title":"Clinical Practice Oncology October"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"ref831","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","author":"Adams","year":"2018","journal-title":"Cytometry A"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2017","journal-title":"Oncotarget"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1042\/bj0311464","article-title":"Electrophoresis of serum globulin: electrophoretic analysis of normal and immune sera","volume":"31","author":"Tiselius","year":"1937","journal-title":"Biochem J"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.25441","article-title":"Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group","volume":"94","author":"Bustoros","year":"2019","journal-title":"Am J Hematol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat Genet"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent Orange exposure and monoclonal gammopathy of undetermined significance: an Operation Ranch Hand veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"ref481","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.843.843","article-title":"Estimating the risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies in the United States: determining demographic differences using a national dataset","volume":"128","author":"Go","year":"2016","journal-title":"Blood"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref991","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref1831","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","author":"Adams","year":"2018","journal-title":"Cytometry A"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"ref1921","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125204","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/cancers12020486","article-title":"Imaging of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"12","author":"Jamet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(09)70234-7","article-title":"Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study","volume":"10","author":"Grass","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u201cessential\u201d hyperglobulinemia with fibrinogenopenia\u2014a new syndrome?","volume":"117","author":"Waldenstr\u00f6m","year":"1944","journal-title":"Acta Med Scand"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref41","first-page":"1","article-title":"Discrete gammaglobulin (M-)components in serum. Clinical study of 150 subjects without myelomatosis","volume":"462","author":"H\u00e4ll\u00e9n","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"key":"ref971","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/blood-2011-11-387324","article-title":"Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics","volume":"119","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"ref1951","article-title":"Guidelines in Multiple Version Accessed To view the most recent version visitNCCN org","volume":"20","author":"KumarSK","year":"2021","journal-title":"Clinical Practice Oncology October"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent Orange exposure and monoclonal gammopathy of undetermined significance: an Operation Ranch Hand veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"51","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref291","first-page":"243","article-title":"Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2013.12.010","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from Nagasaki atomic bomb survivors","volume":"14","author":"Iwanaga","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","article-title":"Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster","volume":"4","author":"Landgren","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10552-015-0685-2","article-title":"Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features","volume":"27","author":"VanValkenburg","year":"2016","journal-title":"Cancer Causes Control"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.70.4.399","article-title":"Electrophoretic patterns of normal and pathological human blood serum and plasma","volume":"70","author":"Longsworth","year":"1939","journal-title":"J Exp Med"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41375-018-0246-2","article-title":"Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics","volume":"33","author":"Clay-Gilmour","year":"2019","journal-title":"Leukemia"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","article-title":"Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria","volume":"37","author":"San Miguel","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/blood-2011-11-387324","article-title":"Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics","volume":"119","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref1971","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"e1139662","DOI":"10.1080\/2162402X.2016.1139662","article-title":"Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro","volume":"5","author":"Kr\u00e4mer","year":"2016","journal-title":"OncoImmunology"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2012-11-466011","article-title":"MGUS prevalence in an ethnically Chinese population in Hong Kong","volume":"121","author":"Wu","year":"2013","journal-title":"Blood"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"ref1481","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.843.843","article-title":"Estimating the risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies in the United States: determining demographic differences using a national dataset","volume":"128","author":"Go","year":"2016","journal-title":"Blood"},{"key":"ref1041","first-page":"1","article-title":"Discrete gammaglobulin (M-)components in serum. Clinical study of 150 subjects without myelomatosis","volume":"462","author":"H\u00e4ll\u00e9n","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ni0708-705","article-title":"Immunology\u2019s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff","volume":"9","author":"Kaufmann","year":"2008","journal-title":"Nat Immunol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(87)90375-5","article-title":"Evaluation of monoclonal gammopathies in the \u201cwell\u201d elderly","volume":"82","author":"Crawford","year":"1987","journal-title":"Am J Med"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"51","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref1981","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128519","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"134","author":"Bustoros","year":"2019","journal-title":"Blood"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/cancers12020486","article-title":"Imaging of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"12","author":"Jamet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref921","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125204","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(87)90375-5","article-title":"Evaluation of monoclonal gammopathies in the \u201cwell\u201d elderly","volume":"82","author":"Crawford","year":"1987","journal-title":"Am J Med"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","article-title":"Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)","volume":"38","author":"Gleeson","year":"2009","journal-title":"Skeletal Radiol"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ijc.28731","article-title":"Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS\/MM","volume":"135","author":"Zwick","year":"2014","journal-title":"Int J Cancer"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2012-11-466011","article-title":"MGUS prevalence in an ethnically Chinese population in Hong Kong","volume":"121","author":"Wu","year":"2013","journal-title":"Blood"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"ref1931","first-page":"1","article-title":"The role of early intervention in high-risk smoldering myeloma","volume":"40","author":"Joseph","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"1756285617746640","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10552-015-0685-2","article-title":"Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features","volume":"27","author":"VanValkenburg","year":"2016","journal-title":"Cancer Causes Control"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41375-018-0246-2","article-title":"Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics","volume":"33","author":"Clay-Gilmour","year":"2019","journal-title":"Leukemia"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ni0708-705","article-title":"Immunology\u2019s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff","volume":"9","author":"Kaufmann","year":"2008","journal-title":"Nat Immunol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2013.12.010","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from Nagasaki atomic bomb survivors","volume":"14","author":"Iwanaga","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1756285617746640","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2017","journal-title":"Oncotarget"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1042\/bj0311464","article-title":"Electrophoresis of serum globulin: electrophoretic analysis of normal and immune sera","volume":"31","author":"Tiselius","year":"1937","journal-title":"Biochem J"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","article-title":"Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster","volume":"4","author":"Landgren","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"e1139662","DOI":"10.1080\/2162402X.2016.1139662","article-title":"Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro","volume":"5","author":"Kr\u00e4mer","year":"2016","journal-title":"OncoImmunology"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","article-title":"Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria","volume":"37","author":"San Miguel","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.25441","article-title":"Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group","volume":"94","author":"Bustoros","year":"2019","journal-title":"Am J Hematol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u201cessential\u201d hyperglobulinemia with fibrinogenopenia\u2014a new syndrome?","volume":"117","author":"Waldenstr\u00f6m","year":"1944","journal-title":"Acta Med Scand"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ijc.28731","article-title":"Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS\/MM","volume":"135","author":"Zwick","year":"2014","journal-title":"Int J Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ejrad.2013.08.036","article-title":"Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM)","volume":"82","author":"Ippolito","year":"2013","journal-title":"Eur J Radiol"},{"key":"ref931","first-page":"1","article-title":"The role of early intervention in high-risk smoldering myeloma","volume":"40","author":"Joseph","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/12\/article-p1720.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/12\/article-p1720.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T13:05:16Z","timestamp":1608901516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/12\/article-p1720.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":196,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7660","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}